Lawrence B. Cohen’s AC Immune ACIU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-12,850
Closed -$36.6K 8
2023
Q3
$36.6K Hold
12,850
0.02% 59
2023
Q2
$38K Hold
12,850
0.02% 64
2023
Q1
$30.1K Hold
12,850
0.02% 60
2022
Q4
$26.2K Hold
12,850
0.01% 91
2022
Q3
$41K Hold
12,850
0.03% 63
2022
Q2
$46K Hold
12,850
0.03% 61
2022
Q1
$51K Hold
12,850
0.03% 63
2021
Q4
$64K Hold
12,850
0.03% 98
2021
Q3
$86K Hold
12,850
0.05% 74
2021
Q2
$102K Hold
12,850
0.05% 72
2021
Q1
$98K Hold
12,850
0.05% 74
2020
Q4
$66K Hold
12,850
0.04% 74
2020
Q3
$63K Sell
12,850
-500
-4% -$3.59K 0.04% 73
2020
Q2
$90K Hold
13,350
0.06% 71
2020
Q1
$92K Hold
13,350
0.07% 70
2019
Q4
$114K Hold
13,350
0.07% 76
2019
Q3
$66K Hold
13,350
0.04% 74
2019
Q2
$74K Hold
13,350
0.05% 73
2019
Q1
$67K Hold
13,350
0.05% 68
2018
Q4
$126K Sell
13,350
-1,500
-10% -$14.2K 0.1% 68
2018
Q3
$119K Sell
14,850
-5,700
-28% -$57.3K 0.08% 68
2018
Q2
$192K Hold
20,550
0.14% 69
2018
Q1
$212K Buy
20,550
+7,500
+57% +$91.2K 0.14% 66
2017
Q4
$167K Hold
13,050
0.11% 68
2017
Q3
$146K Sell
13,050
-20,700
-61% -$177K 0.1% 71
2017
Q2
$297K Buy
+33,750
New +$312K 0.19% 63

Other funds holding ACIU

Lawrence B. Cohen's ACIU Position: Q4 2023 in Review

Lawrence B. Cohen sold out of AC Immune (ACIU) in Q4 2023, closing a stake of 12,850 shares — an estimated $36.6K sold.

Lawrence B. Cohen first reported a position in ACIU in Q2 2017 and held it in 26 quarters. The position peaked at $297K in Q2 2017. 32 funds tracked by Wall St. Rank hold ACIU as of Q4 2023.

  • Lawrence B. Cohen reported no remaining AC Immune position as of Q4 2023 after selling out during the quarter.
  • Lawrence B. Cohen sold 12,850 AC Immune shares in Q4 2023, an estimated $36.6K.
  • Lawrence B. Cohen first reported a position in AC Immune in Q2 2017 and held it in 26 quarters.
  • Lawrence B. Cohen's AC Immune position peaked at $297K in Q2 2017.
  • 32 funds tracked by Wall St. Rank held AC Immune as of Q4 2023.

Based on Lawrence B. Cohen's 13F filing for Q4 2023, filed 9 Feb 2024.